Core Viewpoint - The company, Valiant Biopharma (09887), has seen its stock price increase by over 5%, currently trading at 72.5 HKD, following the completion of patient enrollment in a pivotal clinical study for its drug, Opalizumab (LBL-024), a dual-targeting antibody for treating EP-NEC [1] Group 1 - The pivotal clinical study for Opalizumab (LBL-024), a PD-L1 and 4-1BB dual-targeting antibody, has completed enrollment of all participants [1] - Opalizumab is the first dual-targeting molecule in a pivotal clinical stage aimed at the 4-1BB co-stimulatory receptor, potentially becoming the first approved drug for treating EP-NEC [1] - The 4-1BB agonist can reactivate apoptotic T cells and significantly expand their numbers, making it particularly suitable for treating PD-1/PD-L1 resistant or ineffective cold tumors [1] Group 2 - Besides EP-NEC, Opalizumab has received approval to conduct clinical studies in several cancer types with high unmet clinical needs, including small cell lung cancer (SCLC), biliary tract cancer (BTC), ovarian cancer (OC), non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), liver cancer (HCC), gastric cancer (GC), triple-negative breast cancer (TNBC), and malignant melanoma [1] - Encouraging clinical results have already been observed in SCLC, BTC, and OC, indicating the potential of Opalizumab as an effective anti-tumor drug with a broad range of indications [1]
维立志博涨超5% 近日奥帕替苏米单抗关键注册临床研究完成全部受试者入组